Brentuximab Vedotin,doxorubicin,vinblastine,dacarbazine,nivolumab
Seagen,BMS,takeda
['lymphoma', 'brentuximab', 'hodgkin', 'cml', ' vedo', 'seagen', 'takeda']
brentuximab vedotin + immunotherapy shows 98% orr and 93% cr in patients with early-stage classical hodgkin lymphoma #adc #17icml #lymphoma #oncology #hematology 
ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.